Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ge healthcare a.e. - gadodiamide - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 0,5mmol (287mg)/ml - ineof00854 - gadodiamide - 287.000000 mg - gadodiamide

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

bayer ΕΛΛΑΣ ΑΒΕΕ - gadoxetic acid - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 0,25mmol/ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - Πολλαπλή σκλήρυνση - Επιλεκτικά ανοσοκατασταλτικά - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 και 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

bayer ΕΛΛΑΣ ΑΒΕΕ Σώρου 18-20, 15125 Μαρούσι 210-6187500 - gadobutrol - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 1.0mmol/ml - gadobutrol 604,72mm - gadobutrol

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

mylan ireland limited - fingolimod υδροχλωρική - Η Σκλήρυνση Κατά Πλάκας, Υποτροπιάζουσα-Διαλείπουσα - Ανοσοκατασταλτικά - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 και 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

sandoz pharmaceuticals d.d. (abbr. sandoz d.d.), slovenia verovskova 57, si-1000 ljubljana +386 1 580 2111 - fingolimod hydrochloride - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 0.5mg/cap - fingolimod hydrochloride 0,56mg - fingolimod

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ανοσοκατασταλτικά - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 και 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.